Loading
A phase 1/2 trial of AST-001 in pancreatic ductal adenocarcinoma, run by Ascentawits Pharmaceuticals, Ltd, now recruiting.
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06245330 by Ascentawits Pharmaceuticals, Ltd, with 180 participants planned, started 2022-07-07 and due to reach its primary completion in 2027-08-31. Interventions recorded: AST-001.
Shares Ascentawits Pharmaceuticals and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.